



Florida Restores ADAP Access, but the Fight to Cover a Popular HIV Med Continues

AIDS United urges Gov. DeSantis to sign the urgent HIV legislation into law and secure funding for Florida's AIDS Drug Assistance Program.

March 16, 2026 By [AIDS United](#)

On March 14, the Florida Legislature approved a key amendment from Rep. Jason Brodeur that would allocate \$30 million to the Florida AIDS Drug Assistance Program (ADAP), ensuring that all ADAP enrollees up to 400% of the federal poverty level will continue to maintain access to the program. However, the amendment doesn't reverse the discontinuation of premium assistance for ADAP recipients or the removal of Biktarvy from the state formulary.

We urge Governor DeSantis to swiftly sign the budget proposal that includes emergency funding to the FL ADAP program. Any delay in signing this measure only furthers the anxiety that thousands of people with HIV in Florida have experienced since this unjust decision was announced in January.

We are relieved that the state will ensure that all Florida ADAP enrollees have access to the program to maintain their HIV medication regimens. In our society, people with HIV should never have to worry about whether they will have access to medications that allow them to live.

We are also pleased that the amendment requires the Florida Department of Health to issue monthly budgeting reports to the legislature beginning on April 1, 2026. This will enable crucial transparency around congressionally authorized taxpayer funds on this lifesaving program.

However, we also demand that state leaders work on a solution that will enable premium assistance, as people with HIV depend on consistent and reliable insurance coverage for a range of medical services. People with HIV are not solely navigating life with an HIV diagnosis but also experience a range of other comorbidities and pre-existing conditions that impact all people over the course of a lifespan. People with HIV are whole people with a range of medical concerns. We cannot be satisfied with a solution that leaves people with HIV vulnerable to inadequate healthcare.

Further, we continue to oppose Florida's removal of Biktarvy from the state formulary for ADAP enrollees. Biktarvy is one of the most widely prescribed HIV treatment regimens in the United

States and is recommended as a preferred first-line therapy in the federal HIV treatment guidelines issued by the U.S. Department of Health and Human Services. It has become a standard of care because it provides durable viral suppression, is well tolerated by patients, and has a high barrier to drug resistance.

Forcing patients to switch medications for non-clinical reasons can introduce unnecessary risk, including side effects, adherence challenges, or potential loss of viral suppression. Decisions about HIV treatment should be guided by clinicians and patients based on medical evidence, not by formulary restrictions that disrupt stable care. The removal of a guideline recommended therapy from the state formulary jeopardizes patient health.

Once signed into law by the Governor, people with HIV receiving ADAP services will be able to continue to receive their HIV medications through the FL ADAP program, our fight is not over.

We continue to urge congressional leaders and state representatives across Florida and the nation to fully appreciate the necessity of uninterrupted HIV treatment. Real lives are impacted by ADAP eligibility cuts and restrictions. Draconian proposals put an undue emotional toll on people with HIV.

We will work with our congressional partners to advocate for robust Ryan White Part B funding in the FY27 budget to ensure states can consistently and equitably provide HIV treatment for all who require it.

[This press release](#) was originally published March 15, 2026, on AIDSUnited.org.